Cathay Biotech Inc.
688065.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | CN¥8,106,448 | CN¥8,720,311 | CN¥10,797,271 | CN¥5,346,794 |
| Short-Term Investments | CN¥901,796 | CN¥1,102,641 | CN¥469 | CN¥469 |
| Receivables | CN¥691,958 | CN¥565,264 | CN¥526,618 | CN¥470,435 |
| Inventory | CN¥1,285,422 | CN¥1,162,078 | CN¥1,163,511 | CN¥1,180,528 |
| Other Curr. Assets | CN¥384,259 | CN¥352,780 | CN¥335,602 | CN¥323,117 |
| Total Curr. Assets | CN¥11,491,267 | CN¥12,011,652 | CN¥12,947,798 | CN¥7,386,914 |
| Property Plant & Equip (Net) | CN¥10,088,064 | CN¥9,906,392 | CN¥9,847,542 | CN¥9,848,549 |
| Goodwill | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Intangibles | CN¥685,341 | CN¥690,143 | CN¥692,966 | CN¥685,040 |
| Long-Term Investments | CN¥151,236 | CN¥153,250 | CN¥156,664 | CN¥133,311 |
| Tax Assets | CN¥254,149 | CN¥239,332 | CN¥220,611 | CN¥210,368 |
| Other NC Assets | CN¥775,050 | CN¥820,415 | CN¥824,287 | CN¥757,295 |
| Total NC Assets | CN¥11,953,841 | CN¥11,809,531 | CN¥11,742,070 | CN¥11,634,563 |
| Other Assets | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Total Assets | CN¥23,445,108 | CN¥23,821,183 | CN¥24,689,868 | CN¥19,021,477 |
| Liabilities | – | – | – | – |
| Payables | CN¥1,395,356 | CN¥1,350,425 | CN¥1,369,519 | CN¥1,440,650 |
| Short-Term Debt | CN¥81,473 | CN¥50,385 | CN¥1,012,434 | CN¥1,246,912 |
| Tax Payable | CN¥0 | CN¥45,748 | CN¥0 | CN¥42,848 |
| Deferred Revenue | CN¥30,629 | CN¥0 | CN¥37,625 | CN¥0 |
| Other Curr. Liab. | CN¥82,927 | CN¥52,865 | CN¥75,065 | CN¥79,922 |
| Total Curr. Liab. | CN¥1,655,969 | CN¥1,876,142 | CN¥2,538,496 | CN¥2,917,856 |
| LT Debt | CN¥197,755 | CN¥492,685 | CN¥623,310 | CN¥613,263 |
| Deferred Rev, NC | CN¥374,249 | CN¥377,241 | CN¥382,747 | CN¥389,286 |
| Deferred Tax Liab, NC | CN¥199 | CN¥326 | CN¥0 | CN¥0 |
| Other NC Liab. | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Total NC Liab. | CN¥572,203 | CN¥870,252 | CN¥1,006,057 | CN¥1,002,550 |
| Other Liabilities | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Cap. Leases | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Total Liabilities | CN¥2,228,172 | CN¥2,746,393 | CN¥3,544,553 | CN¥3,920,405 |
| Equity | – | – | – | – |
| Pref Stock | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Common Stock | CN¥721,290 | CN¥721,290 | CN¥721,290 | CN¥583,378 |
| Retained Earnings | CN¥2,469,653 | CN¥2,327,646 | CN¥2,443,508 | CN¥2,306,558 |
| AOCI | CN¥14,562,631 | CN¥369,896 | CN¥14,554,145 | CN¥0 |
| Other Equity | CN¥0 | CN¥0 | CN¥0 | CN¥359,644 |
| Total Equity | CN¥17,597,943 | CN¥17,452,567 | CN¥17,563,815 | CN¥11,507,005 |
| Supplemental Information | – | – | – | – |
| Minority Interest | CN¥3,618,993 | CN¥3,622,222 | CN¥3,581,500 | CN¥3,594,067 |
| Total Liab. & Tot. Equity | CN¥23,445,108 | CN¥23,821,183 | CN¥24,689,868 | CN¥19,021,477 |
| Net Debt | -CN¥7,827,221 | -CN¥8,177,241 | -CN¥9,161,527 | -CN¥3,486,619 |